☆ 4.7 Letter

Blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia: a shared clonal origin

LEUKEMIA (2017)

Journal

LEUKEMIA

Volume 31, Issue 5, Pages 1238-1240

Publisher

NATURE PUBLISHING GROUP

DOI: 10.1038/leu.2017.38

Keywords

-

Categories

Oncology Hematology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Review Oncology

Early T-cell precursor lymphoblastic leukemia accompanied by prominent blastic plasmacytoid dendritic cell proliferation mimicking blastic plasmacytoid dendritic cell neoplasm: an exceptional case report and literature review

Hongyan Liao, Jiang Yu, Yu Liu, Sha Zhao, Huanling Zhu, Dongsheng Xu, Nenggang Jiang, Qin Zheng

Summary: This case demonstrates for the first time that prominent pDC proliferation can be associated with lymphoid neoplasms and can exhibit blastic morphology and immunophenotype. The underlying mechanism of the coexistence of these two blastic populations remains unknown.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)

Add to Collection

Article Medicine, Research & Experimental

Blastic Plasmacytoid Dendritic Cell Neoplasm: Progress in Cell Origin, Molecular Biology, Diagnostic Criteria and Therapeutic Approaches

Wei Cheng, Tian-tian Yu, Ai-ping Tang, Ken He Young, Li Yu

Summary: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy derived from plasmacytoid dendritic cells with unclear pathogenesis. Treatment is based on leukemia or lymphoma experience, relapse is quick with drug resistance.

CURRENT MEDICAL SCIENCE (2021)

Add to Collection

Article Oncology

Integrated Clinical Genotype-Phenotype Characteristics of Blastic Plasmacytoid Dendritic Cell Neoplasm

C. Camero Yin, Naveen Pemmaraju, M. James You, Shaoying Li, Jie Xu, Wei Wang, Zhenya Tang, Omar Alswailmi, Kapil N. Bhalla, Muzaffar H. Qazilbash, Marina Konopleva, Joseph D. Khoury

Summary: Mutation and protein-level profiling have expanded our understanding of the pathogenesis of blastic plasmacytoid dendritic cell neoplasm (BPDCN), revealing a high prevalence of somatic mutations involving epigenetic regulators and RNA splicing factors, along with frequent mutations in genes such as ETV6 and IKZF1. Older age, multiple mutations, and mutations in the DNA methylation pathway are poor prognostic factors in BPDCN patients.

CANCERS (2021)

Add to Collection

Article Oncology

Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity matters

Peter-Martin Bruch, Sascha Dietrich, Herve Finel, Ariane Boumendil, Hildegard Greinix, Thomas Heinicke, Wolfgang Bethge, Dietrich Beelen, Christoph Schmid, Hans Martin, Luca Castagna, Christof Scheid, Kerstin Schaefer-Eckart, Joerg Bittenbring, Juergen Finke, Henrik Sengeloev, Mael Heiblig, Jan Cornelissen, Patrice Chevallier, Mohamad Mohty, Stephen Robinson, Silvia Montoto, Peter Dreger

Summary: This retrospective study analyzed the outcomes of 162 adult patients with BPDCN who underwent a first HCT. The study found that MAC (especially TBI-based) significantly improved the prognosis of alloHCT recipients, and autoHCT could be considered for patients who are not eligible for MAC.

LEUKEMIA (2022)

Add to Collection

Review Medicine, General & Internal

Blastic plasmacytoid dendritic cell neoplasm of the breast A case report and review of the literature

Hyo-jae Lee, Hye Mi Park, So Yeon Ki, Yoo-Duk Choi, Sook Jung Yun, Hyo Soon Lim

Summary: This case describes a rare presentation of BPDCN in the breast parenchyma, with no previous reports on the radiologic features of the disease within breast tissue. The patient was diagnosed using diagnostic breast imaging tools and underwent chemotherapy with peripheral blood stem cell transplantation, achieving complete remission.

MEDICINE (2021)

Add to Collection

Article Pathology

E-Cadherin Expression and Blunted Interferon Response in Blastic Plasmacytoid Dendritic Cell Neoplasm

Luisa Lorenzi, Silvia Lonardi, Donatella Vairo, Andrea Bernardelli, Michela Tomaselli, Mattia Bugatti, Sara Licini, Mariachiara Arisi, Lorenzo Cerroni, Alessandra Tucci, William Vermi, Silvia Clara Giliani, Fabio Facchetti

Summary: This study identifies EC as a novel pDC marker of diagnostic relevance in BPDCN. The results suggest a scenario where malignant pDCs promote the blunting of IFN-I signaling through EC-driven signaling, leading to a poorly immunogenic tumor microenvironment.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2021)

Add to Collection

Article Dermatology

Blastic Indeterminate Dendritic Cell Tumor Associated With Chronic Myelomonocytic Leukemia

Austin Ellis, Ismail Elbaz Younes, Haipeng Shao, Xiaohui Zhang

Summary: This article reports a case of multifocal cutaneous blastic indeterminate dendritic cell tumor (BIDCT) in a patient with chronic myelomonocytic leukemia and summarizes its clinicopathological characteristics. The study found that patients with IDCT/BIDCT associated with chronic myelomonocytic leukemia had worse clinical outcomes compared to patients with IDCT not associated with chronic myelomonocytic leukemia.

AMERICAN JOURNAL OF DERMATOPATHOLOGY (2022)

Add to Collection

Article Medical Laboratory Technology

Clinical Characteristics and Diagnosis of Acute Myeloid Leukemia with CD56-Blastic Plasmacytoid Dendritic Cell Neoplasm

Xiaofang Zhang, Yiping Wu, Chen Li, Keming Shen, Ruimin Li

Summary: The aim of this study was to investigate the clinical characteristics and diagnosis of acute myeloid leukemia with CD56- blastic plasmacytoid dendritic cell neoplasm. Three cases of elderly men with acute myeloid leukemia were analyzed retrospectively, and their bone marrow features suggested the diagnosis of acute myeloid leukemia with blastic plasmacytoid dendritic cell neoplasm. Flow cytometry and second generation sequencing were performed to detect abnormalities in myeloid cells and abnormal plasmacytoid dendritic cells, as well as gene mutations in RUNX1 and DNMT3A.

CLINICAL LABORATORY (2023)

Add to Collection

Article Oncology

Mutational landscape of chronic myelomonocytic leukemia in Chinese patients

Yanbo Nie, Liang Shao, Hong Zhang, Colin K. He, Hongyu Li, Junyan Zou, Long Chen, Huaiyue Ji, Hao Tan, Yani Lin, Kun Ru

Summary: CMML patients in China exhibit a unique mutational spectrum, with common mutations in epigenetic modifiers (TET2 and ASXL1), signaling transduction pathway components (NRAS), and splicing factor (SRSF2). DNMT3A, ETV6, FLT3, and NPM1 mutations are associated with progression to sAML. ASXL1 mutation and treatment modalities are independent prognostic factors for CMML.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Patients with blastic plasmacytoid dendritic cell neoplasm in pregnancy: A rare case report

Li Zhang, Yidong Wang, Mingming Lu, Mengdan Shen, Zhao Duan

Summary: This study presents a case of a 37-year-old pregnant woman with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). It suggests that pregnant women diagnosed with BPDCN in the third trimester should promptly terminate the pregnancy for further treatment.

MEDICINE (2022)

Add to Collection

Article Hematology

Profiling endogenous, environmental, and infectious disease mutational signatures in blastic plasmacytoid dendritic cell neoplasms

Corinn Small, Soham Mukerjee, Diwash Jangam, Sumanth Gollapudi, Kunwar Singh, David L. Jaye, Phyu P. Aung, Christiane Querfeld, Keluo Yao, Karen M. Chisholm, Sheeja Pullarkat, Sa Wang, Alejandro Gru, Mohammad Hussaini, Tracy I. George, Robert S. Ohgami

Summary: In this study, the exome sequence data of 9 BPDCN cases were analyzed. Results showed significant genetic changes related to tobacco exposure, aging, nucleotide excision repair deficiency, UV exposure, and endogenous deamination. These findings suggest that environmental and endogenous genetic changes may play a central role in the oncogenesis of BPDCN.

INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2023)

Add to Collection

Review Oncology

Plasmacytoid Dendritic Cells, a Novel Target in Myeloid Neoplasms

Xavier Roussel, Francine Garnache Ottou, Florian Renosi

Summary: Plasmacytoid dendritic cells (pDC) are the main type I interferon-producing cells in humans and are capable of regulating innate and adaptive immune responses. Tumor infiltration by pDC is well-documented in various cancers and is associated with unfavorable clinical outcomes. While Blastic Plasmacytoid Dendritic Cells Neoplasm (BPDCN) is a well-described aggressive leukemia derived from pDCs, the understanding of tumor infiltration by mature pDCs in Myeloid Neoplasms (MN) is limited. This review aims to provide a comprehensive overview of pDC biology in MN, emphasizing the need for further research into pDC oncogenesis and immune responses for better therapeutic strategies.

CANCERS (2022)

Add to Collection

Article Oncology

Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients

Mahsa Khanlari, C. Cameron Yin, Koichi Takahashi, Curtis Lachowiez, Guilin Tang, Sanam Loghavi, Ismael Bah, Wei Wang, Sergej Konoplev, L. Jeffrey Medeiros, Naveen Pemmaraju, Joseph D. Khoury, Sa A. Wang

Summary: This study provides insights into the clonal origin of blastic plasmacytoid dendritic cell neoplasm (BPDCN) by investigating the mutation profiles of bone marrow (BM) hematopoietic cells and BPDCN cells in patients. The study shows a high prevalence of clonal hematopoiesis in BM of BPDCN patients, especially in the elderly. Additionally, it suggests that a low percentage of BM BPDCN infiltrate and stem cell transplant are associated with favorable outcomes.

LEUKEMIA (2022)

Add to Collection

Article Medicine, General & Internal

Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm, Clinical Features and Immunophenotype: A Case Report

Amaranto Suarez, Nathalie Soler, Alejandra Calderon, Bibiana Martinez, Martha Pina

Summary: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and highly aggressive malignancy that affects the skin and hematopoietic system. It is difficult to clinically suspect, and managing skin lesions is challenging due to their slow progression before spreading. We present a case of a patient with isolated skin involvement who later developed CD4+/CD56+ and CD123+ acute leukemia.

CUREUS JOURNAL OF MEDICAL SCIENCE (2023)

Add to Collection

Review Oncology

Genetics and Epigenetics in Neoplasms with Plasmacytoid Dendritic Cells

Florian Renosi, Mary Callanan, Christine Lefebvre

Summary: This review discusses the differential diagnosis between Blastic pDC Neoplasm (BPDCN) and Acute Myeloid Leukemia with pDC expansion (pDC-AML) and their genomic features. Understanding the distinct characteristics of these two diseases is crucial for diagnosis and treatment.

CANCERS (2022)

Add to Collection

Review Oncology

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia

Claudio Cerchione, Alessandra Romano, Naval Daver, Courtney DiNardo, Elias Joseph Jabbour, Marina Konopleva, Farhad Ravandi-Kashani, Tapan Kadia, Maria Paola Martelli, Alessandro Isidori, Giovanni Martinelli, Hagop Kantarjian

Summary: The discovery of mutated isoforms 1 and 2 mutations of isocitrate dehydrogenases (IDH) 1 and 2 has led to the development of individualized treatment strategy in approximately 20% of patients with acute myeloid leukemia (AML). Targeting IDH to promote differentiation and maturation of malignant clone is an emerging strategy in AML, and small molecule inhibitors have shown promising efficacy in phase I/II trials. The contribution of IDH1/IDH2 mutations in leukemogenesis and progress of targeted therapeutics in AML is highlighted in this review.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Health Care Sciences & Services

Fatigue in newly diagnosed acute myeloid leukaemia: general population comparison and predictive factors

Laura B. Oswald, Adriano Venditti, David Cella, Francesco Cottone, Anna Candoni, Lorella Melillo, Roberto Cairoli, Gabriella Storti, Prassede Salutari, Mario Luppi, Francesco Albano, Maria Paola Martelli, Antonio Cuneo, Agostino Tafuri, Silvia Maria Trisolini, Alessia Tieghi, Paola Fazi, Marco Vignetti, Fabio Efficace

Summary: This study found that patients newly diagnosed with AML reported more severe fatigue compared to the general population, with mean differences exceeding the clinical significance threshold. Factors associated with higher pretreatment fatigue levels included female sex, WHO performance status >= 1, and lower platelet levels.

BMJ SUPPORTIVE & PALLIATIVE CARE (2021)

Add to Collection

Article Hematology

Perturbed hematopoiesis in individuals with germline DNMT3A overgrowth Tatton-Brown-Rahman syndrome

Ayala Tovy, Carina Rosas, Amos S. Gaikwad, Geraldo Medrano, Linda Zhang, Jaime M. Reyes, Yung-Hsin Huang, Tastuhiko Arakawa, Kristen Kurtz, Shannon E. Conneely, Anna G. Guzman, Rogelio Aguilar, Anne Gao, Chun-Wei Chen, Jean J. Kim, Melissa T. Carter, Amaia Lasa-Aranzasti, Irene Valenzuela, Lionel Van Maldergem, Lorenzo Brunetti, M. John Hicks, Andrea N. Marcogliese, Margaret A. Goodell, Rachel E. Rau

Summary: This study reveals the impact of DNMT3A mutations on hematopoiesis in TBRS, including changes in blood parameters, alterations in DNA methylation landscape, and potential occurrence of malignancies. This has important clinical implications for the treatment of TBRS patients and DNMT3A-associated hematological disorders.

HAEMATOLOGICA (2022)

Add to Collection

Article Oncology

Systematic Profi ling of DNMT3A Variants Reveals Protein Instability Mediated by the DCAF8 E3 Ubiquitin Ligase Adaptor

Yung-Hsin Huang, Chun-Wei Chen, Venkatasubramaniam Sundaramurthy, Mikolaj Slabicki, Dapeng Hao, Caroline J. Watson, Ayala Tovy, Jaime M. Reyes, Olga Dakhova, Brielle R. Crovetti, Christina Galonska, Minjung Lee, Lorenzo Brunetti, Yubin Zhou, Katrina Tatton-Brown, Yun Huang, Xiaodong Cheng, Alexander Meissner, Peter J. M. Valk, Lionel Van Maldergem, Mathijs A. Sanders, Jamie R. Blundell, Wei Li, Benjamin L. Ebert, Margaret A. Goodell

Summary: This study systematically investigated the methyltransferase activity and protein stability of disease-associated DNMT3A mutations and found that 74% of them were loss-of-function mutations. Half of these mutations exhibited reduced protein stability and were correlated with greater clonal expansion and acute myeloid leukemia development. The study also discovered a regulated destruction mechanism of DNMT3A mediated by the DCAF8 E3 ubiquitin ligase adaptor.

CANCER DISCOVERY (2022)

Add to Collection

Article Hematology

Modeling IKZF1 lesions in B-ALL reveals distinct chemosensitivity patterns and potential therapeutic vulnerabilities

Jason H. Rogers, Rohit Gupta, Jaime M. Reyes, Michael C. Gundry, Geraldo Medrano, Anna Guzman, Rogelio Aguilar, Shannon E. Conneely, Tidie Song, Cade Johnson, Sean Barnes, Carlo D. D. Cristobal, Kristen Kurtz, Lorenzo Brunetti, Margaret A. Goodell, Rachel E. Rau

Summary: The study utilized CRISPR/Cas9 strategies to validate the drug resistance of IKZF1 abnormalities in B-cell acute lymphoblastic leukemia. It was found that IKZF1 knockout cells displayed relative resistance to several common therapies, and transcription profiling revealed changes in cell phenotype and the JAK/STAT signaling pathway after IKAROS loss.

BLOOD ADVANCES (2021)

Add to Collection

Article Oncology

Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol

Monica Messina, Alfonso Piciocchi, Tiziana Ottone, Stefania Paolini, Cristina Papayannidis, Federica Lessi, Nicola Stefano Fracchiolla, Fabio Forghieri, Anna Candoni, Andrea Mengarelli, Maria Paola Martelli, Adriano Venditti, Angelo Michele Carella, Francesco Albano, Valentina Mancini, Bernardi Massimo, Valentina Arena, Valeria Sargentini, Mariarita Sciume, Domenico Pastore, Elisabetta Todisco, Giovanni Roti, Sergio Siragusa, Marco Ladetto, Stefano Pravato, Eleonora De Bellis, Giorgia Simonetti, Giovanni Marconi, Claudio Cerchione, Paola Fazi, Marco Vignetti, Sergio Amadori, Giovanni Martinelli, Maria Teresa Voso

Summary: IDH1/2 mutations are common in acute myeloid leukemia (AML) and represent a therapeutic target. The GIMEMA AML1516 observational protocol confirms that IDH1/2 mutations are frequently detected at diagnosis and emphasizes the importance of recognizing IDH1/2-mutated cases up-front to offer the most appropriate therapeutic strategy, given the availability of IDH1/2 inhibitors. In the subset of IDH1/2-mutated patients, complete remission achievement rate and overall survival at 2 years were similar to IDH1/2-WT patients.

CANCERS (2022)

Add to Collection

Article Biochemistry & Molecular Biology

SiCoDEA: A Simple, Fast and Complete App for Analyzing the Effect of Individual Drugs and Their Combinations

Giulio Spinozzi, Valentina Tini, Alessio Ferrari, Ilaria Gionfriddo, Roberta Ranieri, Francesca Milano, Sara Pierangeli, Serena Donnini, Federica Mezzasoma, Serenella Silvestri, Brunangelo Falini, Maria Paola Martelli

Summary: Drug combination administration is widely used for the treatment of various pathologies. The importance lies in studying the synergy, antagonism, or additivity of specific combinations. SiCoDEA is an easy-to-use tool for analyzing drug combination data with various models.

BIOMOLECULES (2022)

Add to Collection

Article Pharmacology & Pharmacy

From Serendipity to Rational Identification of the 5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one Core as a New Chemotype of AKT1 Inhibitors for Acute Myeloid Leukemia

Andrea Astolfi, Francesca Milano, Deborah Palazzotti, Jose Brea, Maria Chiara Pismataro, Mariangela Morlando, Oriana Tabarrini, Maria Isabel Loza, Serena Massari, Maria Paola Martelli, Maria Letizia Barreca

Summary: This study aims to find novel anti-leukemia drugs. The compound T126 has been identified as a potent AKT1 inhibitor, showing significant effects on growth inhibition and induction of apoptosis in AML cells. This lays the foundation for future development of new AKT1 inhibitors as therapeutic drugs for leukemia.

PHARMACEUTICS (2022)

Add to Collection

Article Hematology

Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia

Brunangelo Falini, Maria Paola Martelli

Summary: The WHO classification of lympho-hemopoietic neoplasms in 2001, 2008, and 2016 has served as the international standard for diagnosis, but significant advancements have been made in myeloid neoplasms since the 4th WHO edition. This has led to the development of the International Consensus Classification (ICC) and the 5th edition of the WHO classification (WHO-HAEM5). This paper reviews and compares these two classifications, focusing on adult myelodysplastic syndromes/neoplasms (MDS) and acute myeloid leukemia (AML), with the aim of providing a useful tool for pathologists, hematologists, and researchers involved in the diagnosis and treatment of these hematological malignancies.

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Add to Collection

Editorial Material Hematology

Mutant NPM1: Nuclear export and the mechanism of leukemogenesis

Brunangelo Falini, Maria Paola Martelli, Lorenzo Brunetti

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Add to Collection

Editorial Material Hematology

Myelodysplastic/myeloproliferative neoplasm with neutrophilia (atypical chronic myeloid leukemia-aCML)

Giovanni Martino, Martina Quintini, Maria Paola Martelli, Stefano Ascani, Stefano Lazzi, Cristina Mecucci

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Add to Collection

Letter Hematology

The NPM1 mutant defines AML irrespective of blast count

Brunangelo Falini, Maria Paola Martelli, Lorenzo Brunetti, Bjorn T. Gjertsen, Vibeke Andresen

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Blinatumomab Redirects Donor Lymphocytes against CD19+ Acute Lymphoblastic Leukemia without Relevant Bystander Alloreactivity after Haploidentical Hematopoietic Stem Cell Transplantation

Antonella Mancusi, Francesco Zorutti, Loredana Ruggeri, Samanta Bonato, Sara Tricarico, Tiziana Zei, Roberta Iacucci Ostini, Valerio Viglione, Rebecca Sembenico, Sofia Sciabolacci, Valeria Cardinali, Massimo Fabrizio Martelli, Cristina Mecucci, Alessandra Carotti, Maria Paola Martelli, Andrea Velardi, Antonio Pierini

Summary: This study demonstrates the feasibility of using blinatumomab and DLI to treat relapses after Treg/Tcon haploidentical HSCT, and suggests that their preemptive use could improve efficacy.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Review Hematology

How I diagnose and treat NPM1-mutated AML

Brunangelo Falini, Lorenzo Brunetti, Maria Paola Martelli

Summary: Mutations of the nucleophosmin (NPM1) gene play a crucial role in adult acute myeloid leukemia (AML), with unique molecular, pathological, and clinical features. Accurate diagnosis and distinction of NPM1-mutated AML from other entities is important for guiding treatment decisions and assessing relapse risk. Monitoring measurable residual disease (MRD) using NPM1 mutations can provide valuable insights for therapeutic management after remission.

BLOOD (2021)

Add to Collection

Article Oncology

Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in mice

Paolo Sportoletti, Daniele Sorcini, Anna G. Guzman, Jaime M. Reyes, Arianna Stella, Andrea Marra, Sara Sartori, Lorenzo Brunetti, Roberta Rossi, Beatrice Del Papa, Francesco Maria Adamo, Giulia Pianigiani, Camilla Betti, Annarita Scialdone, Valerio Guarente, Giulio Spinozzi, Valentina Tini, Maria Paola Martelli, Margaret A. Goodell, Brunangelo Falini

Summary: Recurrent loss-of-function mutations of the BCOR gene are associated with poor prognosis in AML patients, leading to the creation of a mouse model to study this AML genotype. Double knockout mice showed features of acute erythroid leukemia, suggesting potential efficacy of demethylating agents in AEL treatment.

LEUKEMIA (2021)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.